Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial by Harvey B DuBiner & Douglas A Hubatsch
DuBiner and Hubatsch BMC Ophthalmology 2014, 14:151
http://www.biomedcentral.com/1471-2415/14/151RESEARCH ARTICLE Open AccessLate-day intraocular pressure–lowering efficacy and
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Background: Medications to control intraocular pressure (IOP) are frequently preserved using benzalkonium
chloride (BAK), which can negatively affect the ocular surface. Data are needed to assess efficacy and safety of
prostaglandin drugs preserved with and without BAK. The present study compared the efficacy and safety of
BAK-free travoprost 0.004% (TRAV) and BAK 0.02%–preserved bimatoprost 0.01% (BIM) during late-day time
points in patients with open-angle glaucoma or ocular hypertension.
Methods: This was a 12-week, phase 4, randomized, investigator-masked, crossover study. 84 patients with IOP ≥24
and <36 mmHg were randomized 1:1 to receive once-daily TRAV or BIM for 6 weeks followed by an additional 6-week
crossover period. IOP was measured at the end of each treatment period at 4, 6, and 8 pm. TRAV was considered
noninferior to BIM if the upper limit of the 95% CI of the between-group difference in mean IOP was ≤1.5 mmHg.
Adverse events were assessed throughout the study.
Results: One patient discontinued due to allergic conjunctivitis, and 2 patients with missing data were
excluded; 81 patients were included in the per-protocol population (mean ± SD age, 58.3 ± 11.4 years; TRAV/BIM,
n = 41; BIM/TRAV, n = 40). After 6 weeks, mean IOP with TRAV (17.4 ± 2.7 mmHg; change from baseline, −6.0 mmHg)
was similar to BIM (17.2 ± 2.6 mmHg; change from baseline, −6.3 mmHg); the between-group difference was
0.22 mmHg (95% CI, −0.22 to 0.67). Thus, noninferiority of TRAV versus BIM was demonstrated. Mean IOP at each time
point and mean and percentage IOP change from baseline were not significantly different between treatments. All
treatment-emergent adverse events were mild to moderate. The incidences of mild ocular hyperemia with TRAV and
BIM were 31% and 39%, respectively; moderate hyperemia was observed in 2% of patients receiving BIM.
Conclusion: Late-day IOP-lowering efficacy of BAK-free TRAV was noninferior to that of BAK 0.02%–preserved BIM; both
reduced baseline IOP by 25%. Both treatments were well tolerated, although a higher incidence of moderate ocular
hyperemia was observed with BIM.
Trial registration: ClinicalTrials.gov identifier, NCT01464424; registered November 1, 2011.
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Glaucoma is the second-leading cause of blindness world-
wide and is a chronic, progressive disorder [1]. Elevated
intraocular pressure (IOP) has been associated with in-
creased risk [2] and progression [3,4] of glaucoma, includ-
ing loss of visual field [2-4] and optic disc deterioration
[2]. Because of this, lowering IOP through mechanical
(surgical/laser) or pharmaceutical means is the primary
therapeutic recommendation of the American Academy
of Ophthalmologists [1]. Lowering IOP at a single time
point may not adequately reflect changes in peak IOP
because of daily fluctuations in IOP. Indeed, the time
of highest IOP may vary among individuals, with the
peak occurring at a time in the 24-hour period other
than that typically measured during clinical trials [5].
Thus, consistent 24-hour control of IOP is essential.
In decades past, β-blockers were the most commonly
prescribed IOP-lowering medication for patients with
glaucoma; however, use of prostaglandin analogs (e.g., tra-
voprost, bimatoprost, and latanoprost) has increased in
recent years such that they are now the dominant IOP-
lowering medication [6]. In contrast to β-blockers that
decrease IOP by reducing aqueous flow [7], prostaglan-
din analogs exert their effects by increasing uveoscleral
[7-9], and perhaps trabecular [9], aqueous flow. This mech-
anistic difference results in a greater IOP-lowering effect
than that observed with β-blockers [10], an improved
systemic side-effect profile, and a concomitant increase
in patient adherence [11]. However, conjunctival hyperemia
[11,12], eyelash changes [12], induced iris darkening
[12,13], and periocular skin pigmentation [12,13] have
been associated with prostaglandin analogs.
Bimatoprost is a prostamide (i.e., a synthetic analog of
fatty acid amides) indicated for reducing IOP in patients
with open-angle glaucoma or ocular hypertension [14].
In a 12-month pooled analysis of 2 randomized head-to-
head clinical trials, bimatoprost 0.03% preserved with
0.005% benzalkonium chloride (BAK) reduced IOP to a
greater extent than the β-blocker timolol, with mean
percentage IOP reductions from baseline ranging be-
tween 30% and 33% with bimatoprost compared with
20% and 23% with timolol [15]. Subsequent 2-year [16] and
4-year [17] extension studies demonstrated sustained IOP-
lowering efficacy with bimatoprost 0.03% versus timolol,
with a higher incidence of ocular hyperemia reported with
bimatoprost 0.03% (6% − 14%) versus timolol (0% − 3%). To
improve tolerability, the concentration of bimatoprost was
lowered and the concentration of BAK increased 4-fold to
produce a new BAK 0.02%–preserved bimatoprost 0.01%
(BIM) formulation [18]. This new formulation demon-
strated IOP-lowering efficacy slightly lower than that of
bimatoprost 0.03% after 12 months of treatment (range of
BIM IOP change from baseline, −5.2 to −7.8 mmHg; bima-
toprost 0.03% range, −5.6 to −8.0 mmHg) [18] and furtherincreased patient adherence [19]. The incidence of con-
junctival hyperemia, the most common adverse event (AE)
reported with prostaglandin analogs [20], was nonsignifi-
cantly lower with BIM (29% of patients) compared with
bimatoprost 0.03% (37% of patients) [18].
Travoprost 0.004% is a selective agonist for the prosta-
glandin F receptor that reduces IOP in patients with glau-
coma or ocular hypertension to a significantly greater
extent than timolol [20]. Travoprost provides increased
IOP-lowering efficacy for patients who were previously
uncontrolled on other IOP-lowering therapies [21,22]. In
2001, BAK-free, sofZia® (Alcon Laboratories, Inc., Fort
Worth, TX)–preserved travoprost 0.004% (TRAV) became
available as an alternative therapy for patients with con-
comitant ocular surface disease and those with sensitivity
to BAK [23]. In a head-to-head 3-month comparative
study, the IOP-lowering effect of TRAV administered once
daily in the evening was noninferior to travoprost 0.004%
throughout a 24-hour period and was associated with
fewer incidences of ocular hyperemia (TRAV, 6%; travo-
prost 0.004%, 9%) [23]. Use of TRAV also resulted in fewer
ocular AEs than BAK-preserved bimatoprost or latano-
prost [24,25] and was preferred over bimatoprost [25] and
latanoprost [25,26] by patients. Overall, BAK-free TRAV
was associated with similar IOP lowering and fewer ad-
verse ocular surface effects than other BAK-preserved
prostaglandins [24,25]. Furthermore, an integrated ana-
lysis demonstrated that both BAK-preserved travoprost
0.004% and BAK-free TRAV provide IOP control for up to
a full day [27].
The objective of the present study was to compare the
IOP-lowering efficacy and tolerability of BAK-free TRAV
versus BAK 0.02%–preserved BIM during late-day time
points (4, 6, and 8 pm) and to demonstrate noninferior-
ity of TRAV versus BIM efficacy in patients with open-




Eligible patients were ≥18 years of age with a clinical
diagnosis of open-angle glaucoma or ocular hyperten-
sion in ≥1 eye, baseline IOP ≥24 and <36 mmHg in the
study eye at 8 am ±30 minutes after washout of IOP-
lowering medication at 2 eligibility visits, and a best cor-
rected visual acuity (BCVA) of 20/100 or better in each
eye. Patients must have been willing to discontinue other
ocular hypotensive medications during the study and
have, in the opinion of the investigator, IOPs within a
safe range.
Key exclusion criteria included a history of allergy, hyper-
sensitivity, or low tolerance to components of TRAV or
BIM; abnormalities preventing reliable applanation tonom-
etry and examination of the anterior chamber; intraocular
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progressive retinal or optic nerve disease; or use of sys-
temic medications known to affect IOP, unless on a stable
regimen for ≥7 days before screening. Patients who could
not safely discontinue use of all IOP-lowering medications
for a minimum period of 3 ± 1 to 28 ± 1 days before enroll-
ment, had participated in any other investigational study
≤30 days before screening, or had used any systemic (oral),
injectable, or topical steroids were also excluded.
Study design and treatment
This phase 4, randomized, prospective, crossover,
investigator-masked, controlled study was conducted by a
single investigator at 2 US investigational centers
(ClinicalTrials.gov identifier, NCT01464424) from October
2011 to June 2012. Investigators and study personnel were
masked to patient information and treatment groups. The
study received institutional review board approval from
Institutional Review Board Services (Independent Central
Institutional Review Board, Aurora, Ontario, Canada) and
complied with the ethical standards set forth by the Declar-
ation of Helsinki and Good Clinical Practice. All patients
provided written informed consent before any screen-
ing procedures were performed.
The study consisted of 2 consecutive 6-week study pe-
riods without an intervening washout phase. In the first
phase, patients were randomized 1:1 to TRAV (TRAVA-
TAN Z®, Alcon Laboratories, Inc.) or BIM (Lumigan®,
Allergan, Irvine, CA); in the second phase, patients were
crossed over to the alternate treatment. Randomization
was performed by independent biostatisticians (Howard
M. Proskin & Associates; Rochester, NY) using a random
variate generator (SAS, release 9.1; SAS Institute, Cary,
NC) that assigned patients to 1 of 2 treatment groups
(TRAV to BIM, BIM to TRAV) in 25 successive blocks,
with 2 patients from each treatment group in each block.
Phase 1 consisted of 4 study visits: 1 screening visit,
2 eligibility visits, and 1 follow-up visit after 6 weeks of
treatment with the first medication. At the screening
visit, patients were evaluated for eligibility and asked to
discontinue use of all IOP-lowering medications before
returning for the first eligibility assessment. The 2 eligi-
bility visits occurred 3 to 8 days apart. During these
visits, adherence to the medication washout period and any
changes in concomitant medications were documented.
Patients who qualified for the study (i.e., had IOP ≥24
and <36 mmHg at 8 am) had 1 eye designated as the
study eye during the second eligibility visit. If only
1 eye met the IOP criteria and was to receive study
medication, that eye was appointed the study eye; if
both eyes were to receive medication, the eye with the
highest IOP at baseline (i.e., the second eligibility visit)
was the study eye; and if baseline IOP was equal in
both eyes, the right eye was designated as the studyeye. Eligible patients received 2 bottles of appropriate
study medication and were instructed to administer
the medication to the study eye once daily at 8 pm for
6 weeks.
The first study visit occurred in the afternoon approxi-
mately 6 weeks ±3 days after the second eligibility visit; the
second study visit occurred approximately 6 weeks ±3 days
after the first study visit (i.e., study week 12). The date and
time of the last instillation of the study medication were
documented at both study visits; if a patient had not ad-
ministered the medication during the evening before the
study visit, the visit was rescheduled. During the first study
visit, the second crossover medication was dispensed with
directions for administration identical to that of the first
study medication, once daily at 8 pm for 6 weeks.
Changes in medical health and concomitant medica-
tions, BCVA, slit lamp, IOP measurements, and ocular
hyperemia grading were assessed at all visits. BCVA was
performed using a Snellen visual acuity chart. Slit-lamp bio-
microscopy was used to evaluate ocular signs (e.g., corneal,
lens, eyelids/conjunctiva, iris/anterior chamber) before all
IOP measurements. IOP was assessed at 8 am ±30 minutes
at the screening and first and second eligibility visits, and at
4, 6, and 8 pm ±30 minutes at the second eligibility visit
(baseline) if the IOPs qualified. During all study visits,
Goldmann applanation tonometry was used. Solicited and
unsolicited AEs were recorded at all study visits.
Outcomes
The primary efficacy endpoint was comparison of mean
IOP averaged across 3 late-day time points (4, 6, and
8 pm) after 6 weeks of treatment to demonstrate nonin-
feriority. Secondary endpoints were between-group com-
parison of mean IOP values at each 4, 6, and 8 pm time
point; differences in mean change in IOP from baseline;
and percentage change from baseline. Exploratory ana-
lyses evaluated between-group differences in conjunc-
tival hyperemia severity after 6 weeks of treatment.
Solicited and unsolicited AEs and serious AEs were col-
lected throughout the study and were coded using the
Medical Dictionary for Regulatory Activities Version
15.0. AEs were associated with the treatment adminis-
tered most recently before the time the event was reported.
Treatment-emergent AEs were those that occurred on or
after the date of first drug administration.
Data analysis and statistics
Efficacy analyses were performed in the study eye in the
intent-to-treat (ITT) population (i.e., all patients receiv-
ing study medication and having ≥1 on-therapy study
visit) and the per-protocol (PP) population (i.e., all patients
receiving study medication, completing all study visits per
protocol timelines and criteria, and satisfying inclusion/
exclusion criteria). Safety data, including conjunctival
Table 1 Patient demographics
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tion (i.e., all patients receiving study medication). Effi-
cacy data for the PP population are presented.
Efficacy parameters were analyzed using an analysis of
variance (ANOVA) model that included sequence, period,
and treatment as fixed factors and patient within sequence
as a random factor. A 2-sided 95% CI was constructed for
the difference between mean IOP values for the 2 study
treatments. Noninferiority of TRAV compared with BIM
was supported if the upper limit of the 95% CI for the
between-treatment difference in mean IOP was ≤1.5 mmHg.
For exploratory statistical analyses, ocular hyperemia scale
ordinal response data were converted to a numerical scale:
0 = none/trace, 1 =mild, 2 =moderate, 3 = severe. Differ-
ences in ocular hyperemia from baseline to study com-
pletion were evaluated using Wilcoxon signed-rank tests.
Between-group occurrences of rates of AEs were com-
pared using McNemar tests. All statistical analyses were
performed by an independent biostatistician using SAS,
release 9.1.3 or higher (SAS Institute).
Based on an assumed between-patient SD of 3.0 mmHg
across treatment groups, a within-patient correlation of
0.5 mmHg between IOP values, and a mean IOP for
TRAV less than or equal to BIM, a sample size of 74 pa-
tients was calculated to provide 80% power to detect a
mean IOP difference of 1.5 mmHg between groups.
Results
Patients
A total of 84 patients were enrolled, randomized to
treatment, and included in the safety population (TRAV
followed by BIM [TRAV/BIM], n = 42; BIM followed by
TRAV [BIM/TRAV], n = 42; Figure 1). Of these, 1 patient
in the BIM/TRAV group discontinued during the first
study period (BIM) because of an AE (allergic conjunctiv-
itis); therefore, 83 patients were included in the ITT data-
set (TRAV/BIM, n = 42; BIM/TRAV, n = 41). Two patients
had missing data at the IOP measurement visits and were
excluded from the PP population; thus, the PP population
consisted of 81 patients (TRAV/BIM, n = 41; BIM/TRAV,
n = 40). The mean age ± SD of the PP population wasFigure 1 Patient flow. ITT = intent to treat; PP = per protocol.58.3 ± 11.4 years (range, 26–81). Most patients were
women (67%; n = 54/81) and black (62%; n = 50/81;
Table 1).
Efficacy
In the PP population, mean late-day IOP at baseline was
23.5 ± 3.2 mmHg. After 6 weeks of treatment, mean late-
day IOP was similar between TRAV (17.4 ± 2.7 mmHg)
and BIM (17.2 ± 2.6 mmHg; Figure 2A). The between-
group difference in mean IOP was 0.22 mmHg
(95% CI, −0.22 to 0.67). Because the upper limit of this
95% CI was ≤1.5 mmHg, the IOP-lowering efficacy of
TRAV was found to be noninferior to that of BIM.
Mean IOP measurements at each late-day time point
(4, 6, and 8 pm) after 6 weeks of treatment were similar and
ranged between 17 and 18 mmHg. Mean IOP was similar
between TRAV and BIM at each time point (Figure 2B).
The largest between-group difference occurred at the 4 pm
time point (between-group difference, 0.61 mmHg
[95% CI, −0.03 to 1.26]), but this difference was not
significant (P = 0.062). Changes in IOP from baseline
after 6 weeks of treatment were also not significantly
different between TRAV and BIM at all time points.
IOP reduction with TRAV ranged from −6.4 mmHg at
4 pm to −5.8 mmHg at 8 pm (overall mean IOP ± SD
reduction, −6.0 ± 3.2 mmHg). Similar reductions were ob-
served with BIM (−7.0 mmHg at 4 pm to −5.7 mmHg at
8 pm; overall mean IOP reduction, −6.3 ± 2.8 mmHg).
Similarly, the overall percentage IOP reduction from base-
line was not significantly different between TRAV and
BIM (−25% and −26%, respectively; between-group com-
parison, P = 0.25). Percentage change from baseline at
each time point was 26%, 24%, and 24% at 4, 6, and 8 pm,
respectively, for TRAV and 28%, 25%, and 24% for BIM.
Safety
One serious AE (a fall from a gurney in the emergency
room) was reported in a patient in the TRAV/BIM group
and was not considered to be related to study drug. TenPer-protocol population
Demographic (n = 81)
Age








pm pm pm pm pm pm
Figure 2 Mean IOP at baseline and after 6 weeks of treatment
with TRAV vs BIM. (a) Mean ± SD IOP across time points (i.e., mean
of 4, 6, and 8 pm assessments). (b) Mean IOP at individual time
points (TRAV, n = 80 at the 4 and 8 pm time points). BIM = bimatoprost
0.01%; IOP = intraocular pressure; TRAV = benzalkonium chloride–free
travoprost 0.004%.
Table 2 Treatment-emergent adverse events
(safety population)
TRAV BIM
(n = 84) (n = 84)
Total TEAEs, n* 5 5
Patients with ≥1 TEAE, n (%) 2 (2) 4 (5)
TEAEs, n (%)
Chalazion 1 (1) 0
Allergic conjunctivitis 0 1 (1)
Eye irritation 0 1 (1)
Vitreous floater 0 1 (1)
Bronchitis 1 (1) 0
Upper respiratory tract infection 0 1 (1)
Urinary tract infection 1 (1) 0
Fall 1 (1) 0
Panic attack 1 (1) 0
Face swelling 0 1 (1)
BIM = bimatoprost 0.01%; TEAE = treatment-emergent adverse event;
TRAV = benzalkonium chloride–free travoprost 0.004%.
*Reflects all adverse events for all patients.
Table 3 Abnormal ocular signs* (safety population)





Lens 46 (27) 44 (27) 44 (27)
Cornea 16 (10) 13 (8) 16 (10)
Conjunctiva 8 (5) 8 (5) 10 (6)
Lids/lashes 0 1 (1) 1 (1)
Anterior chamber 0 0 0
Iris 0 0 0
BIM = bimatoprost 0.01%; TRAV = benzalkonium chloride–free
travoprost 0.004%.
*Ocular signs evaluated via slit-lamp examination.
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BIM (TRAV, n = 5; BIM, n = 5) in 6 patients (TRAV, n =
2/84 [2%]; BIM, n = 4/84 [5%]). Eye disorders were the
most common class of treatment-emergent AEs overall
(TRAV, n = 1 [1%]; BIM, n = 3 [4%]; Table 2). There were
no substantial changes in BCVA from baseline to week 6
for either treatment. No clinically significant alterations
in slit-lamp parameters were observed in either treat-
ment group (Table 3). The incidence of abnormal find-
ings of the lens (27% each for TRAV and BIM) and
conjunctiva (TRAV, 5%; BIM, 6%) was similar between
groups.
At baseline, 93% of patients (n = 77/83) were scored with
“none/trace” hyperemia in the study eye, and 7% (n = 6/83)were scored with mild conjunctival hyperemia. After
6 weeks of treatment with TRAV, 69% of patients (n =
29/42) were scored with “none/trace” hyperemia in the
study eye. Mild hyperemia was observed in 31% of pa-
tients receiving TRAV (n = 13/42), 1 of whom had mild
hyperemia at baseline. After 6 weeks of treatment with
BIM, 59% of patients (n = 24/41) were scored with “none/
trace” hyperemia in the study eye. Mild hyperemia was ob-
served in 39% of patients receiving BIM (n = 16/41), with
4 patients having displayed mild hyperemia at baseline.
Moderate hyperemia was reported by 2% of patients (n =
1/41) receiving BIM and 0% of patients receiving TRAV.
All incidences of hyperemia were considered to be related
to treatment. No incidences of severe hyperemia were
reported.
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This prospective crossover study was the first to com-
pare the late-day IOP-lowering efficacy and tolerability
of BAK-free TRAV and BAK 0.02%–preserved BIM in
patients with open-angle glaucoma or ocular hyperten-
sion. Mean IOP after 6 weeks of treatment with TRAV
was similar to that observed with BIM, indicating that
TRAV is noninferior to BIM for IOP lowering. Mean IOP
after 6 weeks of therapy ranged from 17 to 18 mmHg
(a reduction of approximately 6.0 mmHg from base-
line) in both treatment groups. TRAV and BIM were
both well tolerated, and no substantial changes were
observed in BCVA or ocular signs with either TRAV or
BIM. After 6 weeks of treatment, the incidence of mild
hyperemia was greater for patients receiving BIM
(39%) compared with those receiving TRAV (31%); in
addition, the incidence of moderate hyperemia was
greater with BIM (2%) than with TRAV (0%).
To date, few studies have compared the IOP-lowering
efficacy and safety of TRAV with other prostaglandin an-
alogs. In a large, prospective open-label trial in patients
who required transition to a different prostaglandin ther-
apy because of tolerability concerns, mean IOP after
3 months of treatment with TRAV (17 mmHg) was the
same as that observed during patients’ previous treat-
ment with bimatoprost 0.03% [25]. Studies comparing
TRAV with the prostaglandin analog latanoprost have pro-
duced somewhat conflicting results [24-26]. In a 3-month,
randomized treatment-switching trial (n = 22) [24] and a
smaller (n = 20) 3-month, open-label study [26], no sub-
stantial between-group differences in IOP-lowering effect
were observed when patients were switched from latano-
prost 0.005% to TRAV. However, an open-label switching
trial in patients who required alternative IOP-lowering
therapy because of tolerability issues demonstrated a
significant reduction in IOP after 3 months when pa-
tients were switched from latanoprost 0.005% to TRAV
(n = 476) [25].
The IOP-lowering efficacy of BAK-free TRAV and BAK
0.02%–preserved BIM was similar in this study, and the
efficacy of these formulations is similar to that of their
more commonly studied formulations, BAK 0.015%–
preserved travoprost 0.004% and BAK 0.005%–preserved
bimatoprost 0.03%. In 2 meta-analyses, the IOP-lowering
effect was comparable among the 3 most common prosta-
glandins (i.e., travoprost 0.004%, latanoprost 0.005%, and
bimatoprost 0.03%) [20,28]. Because IOP-lowering efficacy
is similar among prostaglandin analogs, treatment may be
greatly affected by tolerability. Ocular hyperemia is the
most common ocular AE observed with prostaglandin an-
alogs [20]. The reduced incidence of mild and moderate
hyperemia observed with TRAV versus BIM in the current
study is consistent with results from a prospective
treatment-switching study that compared TRAV withbimatoprost 0.03% [25]. Furthermore, BAK-preserved
eye drops have been associated with increased ocular
discomfort and ocular surface irritation compared with
BAK-free medications in patients with ocular hyperten-
sion or open-angle glaucoma [29]. Given the similar IOP-
lowering efficacy and reduced severity of hyperemia with
TRAV compared with BIM, patients may benefit from the
use of a BAK-free formulation of TRAV.
This study had several limitations. Assessments were
performed at 2 study centers by the same investigator,
resulting in a relatively limited patient population. Also,
IOP was not measured throughout the entire circadian
period. Although this study sought to augment current
literature, which predominantly assessed IOP lowering
during clinic hours (e.g., 8 am to 4 pm), by providing
evidence of the IOP-lowering efficacy of TRAV after
office hours, measurement of IOP during a complete
24-hour period may have allowed greater comparison.
Furthermore, treatment compliance was not assessed
in this study.Conclusion
This study assessed the efficacy and tolerability of TRAV
versus BIM in patients with open-angle glaucoma or
ocular hypertension. The IOP-lowering efficacy of TRAV
was noninferior to that of BIM, with both treatments re-
ducing IOP by approximately 25% (6 mmHg) at late-day
time points. Both treatments were well tolerated, although
a greater incidence of mild and moderate hyperemia was
observed with BIM.
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